PURPOSE: To compare the therapeutic effect of rimonabant, a new drug which is a selective antagonist of CB1 receptors, with the sibutramine. METHODS: It is an experimental clinical trial, prospective, placebo controlled. Our test was performed in 38 rats, adults females with a hyper caloric diet. We collected their blood 3 times and weighted them once a week. We divided the rats in 3 groups: Rimonabant, Sibutramine and Control. Statistic analysis has been made through ANOVA test, Tukey test and t Student test. RESULTS: The Rimonabant group demonstrated a significant reduction of the weight increase in rats. The Sibutramine group showed a significant reduction on blood glycemia compared to Rimonabant group and Control group. CONCLUSIONS: Rim...
Rimonabant is a first selective blocker of the cannabinoid receptor type 1 (CB1) being developed for...
Objective: To evaluate the effect of bethanechol on blood glucose levels in euglycemic Wistar albino...
Abstract: Administration of the cannabinoid CB1 receptor antagonist, rimonabant (also known as SR 14...
Effects of CB1 receptor antagonist, rimonabant on body weight gain (A) and food intake (B). LETO or ...
Sibutramine is a serotonin-noradrenaline reuptake inhibitor (SNRI) which has been shown to be a saf...
Recent pharmacological findings regarding rimonabant, an anorectic and cannabinoid type 1 receptor (...
The impact of visceral obesity epidemic on the incidence of diabetes mellitus and cardiovascular dis...
Color poster with text and graphs (Spring 2009)Obesity is a leading cause of premature illness and d...
PURPOSE: To explore the interaction between antiobesity drug, topiramate, and hypolipidemic drug, at...
Obesity is a major risk factor in the development of chronic renal failure. Rimonabant, a cannabinoi...
peer reviewedThe present paper is reviewing the current place of weight-reducing drugs in the overal...
Rimonabant is the first CB1 receptor inhibitor available in the Brazilian market. This new drug has ...
OBJECTIVE: Blockade of the CB1 receptor is one of the promising strategies for the treatment of obes...
Background: The incidence of obesity is increasing worldwide, and in the USA approximately 100 milli...
RATIONALE: Pathological impulsivity is a prominent feature in several psychiatric disorders, but det...
Rimonabant is a first selective blocker of the cannabinoid receptor type 1 (CB1) being developed for...
Objective: To evaluate the effect of bethanechol on blood glucose levels in euglycemic Wistar albino...
Abstract: Administration of the cannabinoid CB1 receptor antagonist, rimonabant (also known as SR 14...
Effects of CB1 receptor antagonist, rimonabant on body weight gain (A) and food intake (B). LETO or ...
Sibutramine is a serotonin-noradrenaline reuptake inhibitor (SNRI) which has been shown to be a saf...
Recent pharmacological findings regarding rimonabant, an anorectic and cannabinoid type 1 receptor (...
The impact of visceral obesity epidemic on the incidence of diabetes mellitus and cardiovascular dis...
Color poster with text and graphs (Spring 2009)Obesity is a leading cause of premature illness and d...
PURPOSE: To explore the interaction between antiobesity drug, topiramate, and hypolipidemic drug, at...
Obesity is a major risk factor in the development of chronic renal failure. Rimonabant, a cannabinoi...
peer reviewedThe present paper is reviewing the current place of weight-reducing drugs in the overal...
Rimonabant is the first CB1 receptor inhibitor available in the Brazilian market. This new drug has ...
OBJECTIVE: Blockade of the CB1 receptor is one of the promising strategies for the treatment of obes...
Background: The incidence of obesity is increasing worldwide, and in the USA approximately 100 milli...
RATIONALE: Pathological impulsivity is a prominent feature in several psychiatric disorders, but det...
Rimonabant is a first selective blocker of the cannabinoid receptor type 1 (CB1) being developed for...
Objective: To evaluate the effect of bethanechol on blood glucose levels in euglycemic Wistar albino...
Abstract: Administration of the cannabinoid CB1 receptor antagonist, rimonabant (also known as SR 14...